232 related articles for article (PubMed ID: 31373712)
1. Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
Carmody JK; Plevinsky J; Peugh JL; Denson LA; Hyams JS; Lobato D; LeLeiko NS; Hommel KA
Aliment Pharmacol Ther; 2019 Oct; 50(8):911-918. PubMed ID: 31373712
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis S; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo P; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis A; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Britt A; Saul B; Gotman N; Wang J; Serrano J; Kugathasan S; Walters T; Denson LA
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):855-868. PubMed ID: 28939374
[TBL] [Abstract][Full Text] [Related]
3. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
Hyams JS; Davis Thomas S; Gotman N; Haberman Y; Karns R; Schirmer M; Mo A; Mack DR; Boyle B; Griffiths AM; LeLeiko NS; Sauer CG; Keljo DJ; Markowitz J; Baker SS; Rosh J; Baldassano RN; Patel A; Pfefferkorn M; Otley A; Heyman M; Noe J; Oliva-Hemker M; Rufo PA; Strople J; Ziring D; Guthery SL; Sudel B; Benkov K; Wali P; Moulton D; Evans J; Kappelman MD; Marquis MA; Sylvester FA; Collins MH; Venkateswaran S; Dubinsky M; Tangpricha V; Spada KL; Saul B; Wang J; Serrano J; Hommel K; Marigorta UM; Gibson G; Xavier RJ; Kugathasan S; Walters T; Denson LA
Lancet; 2019 Apr; 393(10182):1708-1720. PubMed ID: 30935734
[TBL] [Abstract][Full Text] [Related]
4. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
Bello C; Belaiche J; Louis E; Reenaers C
J Crohns Colitis; 2011 Jun; 5(3):196-202. PubMed ID: 21575881
[TBL] [Abstract][Full Text] [Related]
5. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Pedersen N; Thielsen P; Martinsen L; Bennedsen M; Haaber A; Langholz E; Végh Z; Duricova D; Jess T; Bell S; Burisch J; Munkholm P
Inflamm Bowel Dis; 2014 Dec; 20(12):2276-85. PubMed ID: 25248002
[TBL] [Abstract][Full Text] [Related]
6. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
Khan N; Abbas AM; Bazzano LA; Koleva YN; Krousel-Wood M
Aliment Pharmacol Ther; 2012 Oct; 36(8):755-64. PubMed ID: 22882428
[TBL] [Abstract][Full Text] [Related]
7. Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Turner D; Yerushalmi B; Kori M; Broide E; Mozer-Glassberg Y; Shaoul R; Kolho KL; Shteyer E; Shamaly H; Ledder O; Cohen S; Peleg S; On A; Levine A
J Crohns Colitis; 2017 May; 11(5):527-533. PubMed ID: 28453754
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
Safroneeva E; Vavricka SR; Fournier N; Straumann A; Rogler G; Schoepfer AM
Inflamm Bowel Dis; 2015 Jun; 21(6):1348-58. PubMed ID: 25806845
[TBL] [Abstract][Full Text] [Related]
9. The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
Kruis W; Leifeld L; Morgenstern J; Pfützer R; Reimers B; Ceplis-Kastner S;
J Crohns Colitis; 2013 May; 7(4):e125-32. PubMed ID: 22951030
[TBL] [Abstract][Full Text] [Related]
10. A practical guide to the management of distal ulcerative colitis.
Ardizzone S; Bianchi Porro G
Drugs; 1998 Apr; 55(4):519-42. PubMed ID: 9561342
[TBL] [Abstract][Full Text] [Related]
11. Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Rubin DT; Bradette M; Gabalec L; Dobru D; Márquez J; Inglis S; Magee E; Solomon D; D'Haens G;
J Crohns Colitis; 2016 Aug; 10(8):925-33. PubMed ID: 26908939
[TBL] [Abstract][Full Text] [Related]
12. Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Watanabe M; Hanai H; Nishino H; Yokoyama T; Terada T; Suzuki Y
Inflamm Bowel Dis; 2013 Jul; 19(8):1681-90. PubMed ID: 23624890
[TBL] [Abstract][Full Text] [Related]
13. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Keil R; Wasserbauer M; Zádorová Z; Kojecký V; Hlava Š; Št'ovíček J; Chudý J; Roznětinská M; Drábek J; Kubišová N; Lochmannová J
Scand J Gastroenterol; 2018 Apr; 53(4):459-465. PubMed ID: 29560753
[TBL] [Abstract][Full Text] [Related]
14. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.
Nikolaus S; Schreiber S; Siegmund B; Bokemeyer B; Bästlein E; Bachmann O; Görlich D; Hofmann U; Schwab M; Kruis W
J Crohns Colitis; 2017 Sep; 11(9):1052-1062. PubMed ID: 28486634
[TBL] [Abstract][Full Text] [Related]
15. Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
Lakatos PL
World J Gastroenterol; 2009 Apr; 15(15):1799-804. PubMed ID: 19370774
[TBL] [Abstract][Full Text] [Related]
16. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.
Zeisler B; Lerer T; Markowitz J; Mack D; Griffiths A; Bousvaros A; Keljo D; Rosh J; Evans J; Kappelman M; Otley A; Kay M; Grossman A; Saeed S; Carvalho R; Oliva-Hemker M; Faubion W; Sudel B; Pfefferkorn M; Ashai-Khan F; Leleiko N; Hyams J;
J Pediatr Gastroenterol Nutr; 2013 Jan; 56(1):12-8. PubMed ID: 22847466
[TBL] [Abstract][Full Text] [Related]
17. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Nguyen NH; Fumery M; Dulai PS; Prokop LJ; Sandborn WJ; Murad MH; Singh S
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):742-753. PubMed ID: 30122356
[TBL] [Abstract][Full Text] [Related]
19. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Yamamoto T; Shimoyama T; Matsumoto K
Aliment Pharmacol Ther; 2015 Sep; 42(5):549-58. PubMed ID: 26140337
[TBL] [Abstract][Full Text] [Related]
20. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
